Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC for Cash

Niagen Bioscience to Streamline and Focus Its Operations With the Sale of Chromadex Reference Standards Business to Lgc in All-Cash Transaction

Niagen Bioscience Inc - Sells Chromadex Business to Lgc in All-Cash Deal

BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside

Niagen Bioscience Inc - Secures New U.S. Patent for Intravenous and Injection Formulations & Methods of Use for Nicotinamide Riboside

Niagen Bioscience Wins New U.S. Patent for IV and Injectable Nicotinamide Riboside Formulations

Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen

Press Release: Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen

Niagen Bioscience Inc - Partners With Truemed to Expand Hsa/FSA Access for Tru Niagen

Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast

Niagen Bioscience Acquires Core Nicotinamide Riboside Patent Portfolio

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (Nr) Patent Portfolio From Queen’s University Belfast

Niagen Bioscience management to meet with Roth Capital

Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience CFO Pamir Ozan Acquires Common Shares

Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups

Niagen Bioscience announces results of Niagen supplementation in long COVID

Niagen Bioscience Reports Clinical Trial Shows Niagen Supplement Boosts NAD+ and Eases Long COVID Symptoms